Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SRx Health Solutions (SRXH) Short-term Investments (2019 - 2023)

SRx Health Solutions (SRXH) has disclosed Short-term Investments for 5 consecutive years, with $6.3 million as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Short-term Investments fell 9.52% year-over-year to $6.3 million, compared with a TTM value of $6.3 million through Mar 2023, down 9.52%, and an annual FY2022 reading of $6.3 million, down 12.66% over the prior year.
  • Short-term Investments was $6.3 million for Q1 2023 at SRx Health Solutions, roughly flat from $6.3 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $7.2 million in Q3 2021 and bottomed at $25000.0 in Q1 2020.
  • Average Short-term Investments over 5 years is $3.9 million, with a median of $6.2 million recorded in 2019.
  • The sharpest move saw Short-term Investments crashed 99.6% in 2020, then surged 11349.21% in 2021.
  • Year by year, Short-term Investments stood at $173000.0 in 2019, then plummeted by 63.58% to $63000.0 in 2020, then soared by 11349.21% to $7.2 million in 2021, then fell by 12.66% to $6.3 million in 2022, then changed by 0.0% to $6.3 million in 2023.
  • Business Quant data shows Short-term Investments for SRXH at $6.3 million in Q1 2023, $6.3 million in Q4 2022, and $7.0 million in Q3 2022.